When was Microchips Biotech founded?

Microchips Biotech was founded in 1999 and raised its 1st funding round 3 years after it was founded.

Where is Microchips Biotech located?

Microchips Biotech is headquartered in Lexington, United States. It is registered at Lexington, Massachusetts.

How many employees does Microchips Biotech have?

As of Aug 31, 2026, the latest employee count at Microchips Biotech is 4.

Is Microchips Biotech a funded company?

Microchips Biotech is a funded company, having raised a total of $90.7M across 7 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jun 17, 2002.

When was the latest funding round of Microchips Biotech?

Microchips Biotech's latest funding was a $***** Series E round on Jun 24, 2015, with participation from 6 investors.

Where does Microchips Biotech rank among its competitors?

Microchips Biotech ranks 246th amongst 2031 active competitors, of which 471 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Antheia, which secured $24M in Jan, 2026.

Who are the top competitors of Microchips Biotech?

Microchips Biotech's top competitors include Synthego, Antheia and Transcenta. Among them, Antheia secured the most recent funding round in January, 2026.

Microchips Biotech - 2026 Company Profile, Team, Funding & Competitors

Microchips Biotech is an acquired company based in Lexington (United States), founded in 1999 by Michael Cima and David H Koch. It operates as a Microchip-based implants for drug delivery. Microchips Biotech has raised $90.7M in funding from investors like Polaris Partners, InterWest Partners and Flybridge Capital Partners. The company has 2031 active competitors, including 471 funded and 353 that have exited. Its top competitors include companies like Synthego, Antheia and Transcenta.

Company Details

Microchips Biotech develops microchip implants for drug delivery. Its platform technology is an implantable microchip that can be inserted in a physician's office under local anesthesia and can be activated or inactivated wirelessly. This microchip can then release preset doses of the device over months and years. Microchips has won a grant from the Bill and Melinda Gates Foundation to use its platform technology to develop an implantable contraceptive device for women with a life of ~16 years. In addition, the company has a partnership with Teva to apply its drug delivery platform for Teva generics in the management of chronic diseases, like osteoporosis. Microchips was co-founded by MIT's Robert Langer and Michael Cima. The technology can be used for therapies that require frequent, long-term dosing, or delivery via injection in diseases such as osteoporosis, diabetes, multiple sclerosis, pain management and several others.

Website: microchipsbiotech.com
Social
Email ID: *****@mchips.com
Registered Address: Lexington, Massachusetts

Key Metrics

Founded Year

1999

Location

Lexington, United States

Stage

Acquired

Total Funding

$90.7M in 7 rounds

Latest Funding Round

Series E, Jun 24, 2015, $*****

Investors

Polaris Partners & 9 more

Ranked

246^th among 2031 active competitors

Employee Count

4 as on Aug 31, 2026

Similar Companies

Synthego & 2767 more

Exit Details

Acquired by Daré Bioscience (Nov 11, 2019)

View Microchips Biotech's full profile

Microchips Biotech is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
MICROCHIPS, INC. CIN: 43469588 , United States, Active	Dec 31, 1999	-	10 (As on Dec 31, 2019)	-

Microchips Biotech got acquired by Daré Bioscience on Nov 11, 2019 at an acquisition amount of $*****.

Click here to take a look at Microchips Biotech's acquisition in detail

Microchips Biotech has raised a total funding of $90.7M over 7 rounds. Its first funding round was on Jun 17, 2002. Its latest funding round was a Series E round on Jun 24, 2015 for $*****. 6 investors participated in its latest round. Microchips Biotech has 10 institutional investors.

Here is the list of recent funding rounds of Microchips Biotech:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 24, 2015	4412401	Series E	2789861	9173107	6564151	1329903
Jan 07, 2010	2114137	Series D	4577259	3109647	4144960	2736692
Mar 06, 2009	7174285	Series C	4682432	4701444	1634774	3960093

Access funding benchmarks and valuations. Sign up today!

View details of Microchips Biotech's funding rounds and investors

The founders of Microchips Biotech are Michael Cima and David H Koch.

Here are the details of Microchips Biotech's key team members:

Michael Cima: Co-Founder & Director of Microchips Biotech and founder of 3 other companies, Taris Biomedical, Microchips Biotech and Springleaf Therapeutics.
David H Koch: Co-Founder of Microchips Biotech.

View details of Microchips Biotech's Founder profiles and Board Members

Microchips Biotech's employee count trend

Microchips Biotech has 4 employees as of Aug 26. Here is Microchips Biotech's employee count trend over the years:

Employee count trend for Microchips Biotech

Uncover Microchips Biotech's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Microchips Biotech include Synthego, Antheia and Transcenta. Here is the list of Top 10 competitors of Microchips Biotech, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Synthego 2012, Redwood City (United States), Acquired	Developer of CRISPR-engineered cell and gene therapies	$460M	8VC, Perceptive Advisors & 30 others	71/100
2nd	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
3rd	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Temasek & 11 others	66/100
4th	Judges Scientific 2002, London (United Kingdom), Public	Acquisition and development of scientific instrument businesses	-	Origin Capital, Lloyds Banking Group	65/100
5th	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Orbimed, Sino Biopharmaceutical & 18 others	65/100
6th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Cormorant Asset Management, Fidelity Investments ... & 14 others	64/100
7th	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Demeter, Bpifrance & 14 others	63/100
8th	Microban 1994, Huntersville (United States), Acquired	Antimicrobial and odor control technologies for durable product protection and freshness	$64.6M	UBS, Brown Brothers Harriman & 1 others	63/100
9th	Dewpoint Therapeutics 2018, Boston (United States), Series D	Developer of small molecule based therapeutics	$346M	Maverick Ventures, Polaris Partners & 16 others	62/100
10th	One Biosciences 2020, Paris (France), Series A	Developer of single-cell therapeutics solutions to treat multiple health disorders	$22.4M	BLAST Premier, Redmile Group & 6 others	62/100
246th	Microchips Biotech 1999, Lexington (United States), Acquired	Microchip-based implants for drug delivery	$90.7M	Saints Capital, Medtronic & 8 others	42/100